secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2023-09-11T23:59:59+00:00
Accession:  0001171843-23-005658
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus discontinues AB-161 and coronavirus programs, focuses on HBV; cash runway extended to Q3 2025
--------------------------------------------------------------------------------

- Discontinuing AB-161 (oral RNA destabilizer) due to pre-clinical toxicology finding; no safety issues in Phase 1 single doses.
- Discontinuing coronavirus combination therapy (AB-343) due to unfavorable PK profile in IND-enabling studies.
- Dosed first subject in Phase 1a/1b for oral PD-L1 inhibitor AB-101; preliminary data expected H1 2024.
- Pipeline changes expected to extend cash runway through Q3 2025.
- Ongoing LNP patent litigations against Moderna (claim construction hearing Feb 2024) and Pfizer/BioNTech.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184323005658/0001171843-23-005658-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184323005658/f8k_091123.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-005658

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer